Received May 26, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
Today it is very warm and red; Today it is very warm and red; It is painful but not above and beyond; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of injection site erythema in a patient who received Herpes zoster (Shingrix) for prophylaxis. On 17-MAY-2025, the patient received Shingrix. In MAY-2025, an unknown time after receiving Shingrix, the patient experienced injection site pain (Verbatim: It is painful but not above and beyond). On 18-MAY-2025, the patient experienced injection site erythema (Verbatim: Today it is very warm and red) and injection site warmth (Verbatim: Today it is very warm and red). The outcome of the injection site erythema, injection site pain and injection site warmth were not reported. It was unknown if the reporter considered the injection site erythema, injection site pain and injection site warmth to be related to Shingrix. It was unknown if the company considered the injection site erythema, injection site pain and injection site warmth to be related to Shingrix. Additional Information: GSK receipt date: 18-MAY-2025 The case was reported by the patient via (Shingrix GSK Chatbot) interactive digital media. The patient had a vaccine of Shingrix early afternoon one day prior to the reporting day on Saturday. On the day of reporting, it was very warm and red and about 3 x 3 in diameter. It was painful but not above and beyond. The patient asked that he/she should take Benadryl or put a cold compress on the area. After taking Shingrix how he/she calm the redness and pain.